Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-03-10

AUTHORS

Hiromasa Katoh, Tsuyoshi Nozue, Ichiro Michishita

ABSTRACT

Activated factor-X (FXa) plays an important role not only in the coagulation cascade, but also in pro-inflammatory responses. However, few data exist regarding the anti-inflammatory effect of FXa inhibitors in clinical practice. The aim of this study was to evaluate the anti-inflammatory and anti-atherosclerotic effects of FXa inhibitors in Japanese patients with non-valvular atrial fibrillation (NVAF). Eighty-three patients with NVAF were treated with FXa inhibitors from March 2013 to March 2015 at our institution. Of these, 55 patients who were not pretreated with warfarin or dabigatran (rivarixaban in 23 patients and apixaban in 32) were included in this study. We measured various inflammatory and coagulation markers at baseline and at 6 months after treatment. Plasma concentrations of pentraxin 3 (PTX3) (from 2.45 ± 1.31 to 1.97 ± 1.00 ng/mL, p = 0.0009) and fibrin and fibrinogen degradation products (FDP) D-dimer (from 1.18 ± 0.70 to 0.74 ± 0.32 μg/mL, p < 0.0001) decreased, while those of TM (from 2.9 ± 0.8 to 3.2 ± 0.9 FU/mL, p = 0.003) increased significantly at 6 months. Interestingly, change of each marker denoted the same tendency in both rivaroxaban and apixaban. In conclusion, the present study suggests that FXa inhibitors have not only an anti-coagulant effect but also anti-inflammatory effects in patients with NVAF. Further large-scale prospective study is necessary to evaluate whether changes in these markers will be associated with a lower risk for future cardiovascular events. More... »

PAGES

1130-1136

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00380-017-0962-y

DOI

http://dx.doi.org/10.1007/s00380-017-0962-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084021180

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28283738


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticoagulants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atrial Fibrillation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Coagulation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Factor Xa Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Inflammation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stroke", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417368.f", 
          "name": [
            "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Katoh", 
        "givenName": "Hiromasa", 
        "id": "sg:person.01351172112.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351172112.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417368.f", 
          "name": [
            "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nozue", 
        "givenName": "Tsuyoshi", 
        "id": "sg:person.01033145125.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033145125.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.417368.f", 
          "name": [
            "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Michishita", 
        "givenName": "Ichiro", 
        "id": "sg:person.0732262025.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732262025.70"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00380-015-0694-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027777491", 
          "https://doi.org/10.1007/s00380-015-0694-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00380-015-0719-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040134302", 
          "https://doi.org/10.1007/s00380-015-0719-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00380-013-0400-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003231052", 
          "https://doi.org/10.1007/s00380-013-0400-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-03-10", 
    "datePublishedReg": "2017-03-10", 
    "description": "Activated factor-X (FXa) plays an important role not only in the coagulation cascade, but also in pro-inflammatory responses. However, few data exist regarding the anti-inflammatory effect of FXa inhibitors in clinical practice. The aim of this study was to evaluate the anti-inflammatory and anti-atherosclerotic effects of FXa inhibitors in Japanese patients with non-valvular atrial fibrillation (NVAF). Eighty-three patients with NVAF were treated with FXa inhibitors from March 2013 to March 2015 at our institution. Of these, 55 patients who were not pretreated with warfarin or dabigatran (rivarixaban in 23 patients and apixaban in 32) were included in this study. We measured various inflammatory and coagulation markers at baseline and at 6 months after treatment. Plasma concentrations of pentraxin 3 (PTX3) (from 2.45\u2009\u00b1\u20091.31 to 1.97\u2009\u00b1\u20091.00\u00a0ng/mL, p\u2009=\u20090.0009) and fibrin and fibrinogen degradation products (FDP) D-dimer (from 1.18\u2009\u00b1\u20090.70 to 0.74\u2009\u00b1\u20090.32\u00a0\u03bcg/mL, p\u2009<\u20090.0001) decreased, while those of TM (from 2.9\u2009\u00b1\u20090.8 to 3.2\u2009\u00b1\u20090.9 FU/mL, p\u2009=\u20090.003) increased significantly at 6 months. Interestingly, change of each marker denoted the same tendency in both rivaroxaban and apixaban. In conclusion, the present study suggests that FXa inhibitors have not only an anti-coagulant effect but also anti-inflammatory effects in patients with NVAF. Further large-scale prospective study is necessary to evaluate whether changes in these markers will be associated with a lower risk for future cardiovascular events.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00380-017-0962-y", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1095887", 
        "issn": [
          "0910-8327", 
          "1615-2573"
        ], 
        "name": "Heart and Vessels", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "32"
      }
    ], 
    "keywords": [
      "non-valvular atrial fibrillation", 
      "anti-inflammatory effects", 
      "FXa inhibitors", 
      "atrial fibrillation", 
      "pentraxin 3", 
      "Japanese patients", 
      "large-scale prospective studies", 
      "future cardiovascular events", 
      "anti-atherosclerotic effects", 
      "fibrinogen degradation products D", 
      "pro-inflammatory response", 
      "factor Xa inhibitors", 
      "anti-coagulant effect", 
      "cardiovascular events", 
      "coagulation markers", 
      "prospective study", 
      "plasma concentrations", 
      "lower risk", 
      "clinical practice", 
      "patients", 
      "fibrillation", 
      "inhibitors", 
      "months", 
      "markers", 
      "present study", 
      "product D", 
      "dabigatran", 
      "rivaroxaban", 
      "apixaban", 
      "warfarin", 
      "study", 
      "baseline", 
      "important role", 
      "effect", 
      "treatment", 
      "risk", 
      "fibrin", 
      "coagulation", 
      "conclusion", 
      "same tendency", 
      "aim", 
      "changes", 
      "response", 
      "factors", 
      "role", 
      "events", 
      "concentration", 
      "practice", 
      "institutions", 
      "data", 
      "tendency", 
      "dimer", 
      "Tm"
    ], 
    "name": "Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation", 
    "pagination": "1130-1136", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084021180"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00380-017-0962-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28283738"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00380-017-0962-y", 
      "https://app.dimensions.ai/details/publication/pub.1084021180"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-06-01T22:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_757.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00380-017-0962-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00380-017-0962-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00380-017-0962-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00380-017-0962-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00380-017-0962-y'


 

This table displays all metadata directly associated to this object as RDF triples.

193 TRIPLES      22 PREDICATES      95 URIs      84 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00380-017-0962-y schema:about N1fe8f579416c40d6a61106e461d33a24
2 N309540e79b284380a04ac914cc7d91b4
3 N3abc32aa5d9b4f34b069190a1aa9ef60
4 N5632bf4da3584585a7fc157d1d0f762f
5 N646ae3200f8d4b498406908a024ec091
6 N67fa820efbb34eddac43050aca78eba3
7 N8eff2ffcf8eb4f55a8fe2e20f61fe7ea
8 Na724e92da4dc4b7bbbbba79e36f94555
9 Nb2219f9c133e4bdaaea924937835be19
10 Nc161a973f9f7421eb5a9bc735a5bb9f6
11 Nc28356271c2f4983912355ee26e81667
12 Nd1f4c237f1a040629c7d1c70b1aaf266
13 Ndfcac96e877e4fc8969f72d4af293e7e
14 anzsrc-for:11
15 anzsrc-for:1102
16 schema:author Nee74e41e1585491caf43d9f0dc4221a1
17 schema:citation sg:pub.10.1007/s00380-013-0400-8
18 sg:pub.10.1007/s00380-015-0694-9
19 sg:pub.10.1007/s00380-015-0719-4
20 schema:datePublished 2017-03-10
21 schema:datePublishedReg 2017-03-10
22 schema:description Activated factor-X (FXa) plays an important role not only in the coagulation cascade, but also in pro-inflammatory responses. However, few data exist regarding the anti-inflammatory effect of FXa inhibitors in clinical practice. The aim of this study was to evaluate the anti-inflammatory and anti-atherosclerotic effects of FXa inhibitors in Japanese patients with non-valvular atrial fibrillation (NVAF). Eighty-three patients with NVAF were treated with FXa inhibitors from March 2013 to March 2015 at our institution. Of these, 55 patients who were not pretreated with warfarin or dabigatran (rivarixaban in 23 patients and apixaban in 32) were included in this study. We measured various inflammatory and coagulation markers at baseline and at 6 months after treatment. Plasma concentrations of pentraxin 3 (PTX3) (from 2.45 ± 1.31 to 1.97 ± 1.00 ng/mL, p = 0.0009) and fibrin and fibrinogen degradation products (FDP) D-dimer (from 1.18 ± 0.70 to 0.74 ± 0.32 μg/mL, p < 0.0001) decreased, while those of TM (from 2.9 ± 0.8 to 3.2 ± 0.9 FU/mL, p = 0.003) increased significantly at 6 months. Interestingly, change of each marker denoted the same tendency in both rivaroxaban and apixaban. In conclusion, the present study suggests that FXa inhibitors have not only an anti-coagulant effect but also anti-inflammatory effects in patients with NVAF. Further large-scale prospective study is necessary to evaluate whether changes in these markers will be associated with a lower risk for future cardiovascular events.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree false
26 schema:isPartOf N31645357e75c4fffabd3bb75da638af1
27 N8ac743719ebe44a3a6f9980035454928
28 sg:journal.1095887
29 schema:keywords FXa inhibitors
30 Japanese patients
31 Tm
32 aim
33 anti-atherosclerotic effects
34 anti-coagulant effect
35 anti-inflammatory effects
36 apixaban
37 atrial fibrillation
38 baseline
39 cardiovascular events
40 changes
41 clinical practice
42 coagulation
43 coagulation markers
44 concentration
45 conclusion
46 dabigatran
47 data
48 dimer
49 effect
50 events
51 factor Xa inhibitors
52 factors
53 fibrillation
54 fibrin
55 fibrinogen degradation products D
56 future cardiovascular events
57 important role
58 inhibitors
59 institutions
60 large-scale prospective studies
61 lower risk
62 markers
63 months
64 non-valvular atrial fibrillation
65 patients
66 pentraxin 3
67 plasma concentrations
68 practice
69 present study
70 pro-inflammatory response
71 product D
72 prospective study
73 response
74 risk
75 rivaroxaban
76 role
77 same tendency
78 study
79 tendency
80 treatment
81 warfarin
82 schema:name Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation
83 schema:pagination 1130-1136
84 schema:productId N6752c71172d543d1a92436e3ef0e1205
85 N8ce7c247bdc64435ae0e7710b3775562
86 Nbcc276bf01f74be792405a9db8926444
87 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084021180
88 https://doi.org/10.1007/s00380-017-0962-y
89 schema:sdDatePublished 2022-06-01T22:16
90 schema:sdLicense https://scigraph.springernature.com/explorer/license/
91 schema:sdPublisher N0d77a8de8ad54f67941916aab9af47e7
92 schema:url https://doi.org/10.1007/s00380-017-0962-y
93 sgo:license sg:explorer/license/
94 sgo:sdDataset articles
95 rdf:type schema:ScholarlyArticle
96 N0d77a8de8ad54f67941916aab9af47e7 schema:name Springer Nature - SN SciGraph project
97 rdf:type schema:Organization
98 N1fe8f579416c40d6a61106e461d33a24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Anticoagulants
100 rdf:type schema:DefinedTerm
101 N309540e79b284380a04ac914cc7d91b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Blood Coagulation
103 rdf:type schema:DefinedTerm
104 N31645357e75c4fffabd3bb75da638af1 schema:volumeNumber 32
105 rdf:type schema:PublicationVolume
106 N3abc32aa5d9b4f34b069190a1aa9ef60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Follow-Up Studies
108 rdf:type schema:DefinedTerm
109 N5632bf4da3584585a7fc157d1d0f762f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Aged
111 rdf:type schema:DefinedTerm
112 N646ae3200f8d4b498406908a024ec091 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Humans
114 rdf:type schema:DefinedTerm
115 N6752c71172d543d1a92436e3ef0e1205 schema:name pubmed_id
116 schema:value 28283738
117 rdf:type schema:PropertyValue
118 N67fa820efbb34eddac43050aca78eba3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Treatment Outcome
120 rdf:type schema:DefinedTerm
121 N8ac743719ebe44a3a6f9980035454928 schema:issueNumber 9
122 rdf:type schema:PublicationIssue
123 N8ce7c247bdc64435ae0e7710b3775562 schema:name doi
124 schema:value 10.1007/s00380-017-0962-y
125 rdf:type schema:PropertyValue
126 N8eff2ffcf8eb4f55a8fe2e20f61fe7ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Factor Xa Inhibitors
128 rdf:type schema:DefinedTerm
129 N94d82381b8e14a1e8d4003f7846c30cc rdf:first sg:person.0732262025.70
130 rdf:rest rdf:nil
131 Na724e92da4dc4b7bbbbba79e36f94555 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Atrial Fibrillation
133 rdf:type schema:DefinedTerm
134 Nb2219f9c133e4bdaaea924937835be19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Stroke
136 rdf:type schema:DefinedTerm
137 Nbcc276bf01f74be792405a9db8926444 schema:name dimensions_id
138 schema:value pub.1084021180
139 rdf:type schema:PropertyValue
140 Nc161a973f9f7421eb5a9bc735a5bb9f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Inflammation
142 rdf:type schema:DefinedTerm
143 Nc28356271c2f4983912355ee26e81667 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Male
145 rdf:type schema:DefinedTerm
146 Nd1f4c237f1a040629c7d1c70b1aaf266 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Female
148 rdf:type schema:DefinedTerm
149 Ndb1af84d4c29452d9783631754192c1a rdf:first sg:person.01033145125.12
150 rdf:rest N94d82381b8e14a1e8d4003f7846c30cc
151 Ndfcac96e877e4fc8969f72d4af293e7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Prospective Studies
153 rdf:type schema:DefinedTerm
154 Nee74e41e1585491caf43d9f0dc4221a1 rdf:first sg:person.01351172112.19
155 rdf:rest Ndb1af84d4c29452d9783631754192c1a
156 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
157 schema:name Medical and Health Sciences
158 rdf:type schema:DefinedTerm
159 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
160 schema:name Cardiorespiratory Medicine and Haematology
161 rdf:type schema:DefinedTerm
162 sg:journal.1095887 schema:issn 0910-8327
163 1615-2573
164 schema:name Heart and Vessels
165 schema:publisher Springer Nature
166 rdf:type schema:Periodical
167 sg:person.01033145125.12 schema:affiliation grid-institutes:grid.417368.f
168 schema:familyName Nozue
169 schema:givenName Tsuyoshi
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033145125.12
171 rdf:type schema:Person
172 sg:person.01351172112.19 schema:affiliation grid-institutes:grid.417368.f
173 schema:familyName Katoh
174 schema:givenName Hiromasa
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351172112.19
176 rdf:type schema:Person
177 sg:person.0732262025.70 schema:affiliation grid-institutes:grid.417368.f
178 schema:familyName Michishita
179 schema:givenName Ichiro
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732262025.70
181 rdf:type schema:Person
182 sg:pub.10.1007/s00380-013-0400-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003231052
183 https://doi.org/10.1007/s00380-013-0400-8
184 rdf:type schema:CreativeWork
185 sg:pub.10.1007/s00380-015-0694-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027777491
186 https://doi.org/10.1007/s00380-015-0694-9
187 rdf:type schema:CreativeWork
188 sg:pub.10.1007/s00380-015-0719-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040134302
189 https://doi.org/10.1007/s00380-015-0719-4
190 rdf:type schema:CreativeWork
191 grid-institutes:grid.417368.f schema:alternateName Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan
192 schema:name Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan
193 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...